Our findings indicate that CCL-18 and IL-23 participate in the inflammatory process of COPD and are correlated with irreversible airway inflammation and airflow restriction, so they may be used as inflammatory markers for disease evaluation and efficacy evaluation of COPD. This evidence concerns the gene CCL18 and inflammation.